No Access To EMA Documents For Non-EU Entities As Requests Get Excessively Burdensome
Executive Summary
The European Medicines Agency is facing excessive workload because of high volumes of access to document requests, and has decided not to process requests coming from outside of the EU.
You may also be interested in...
Pharma firms way ahead in requesting access to EMA documents
When the European Medicines Agency was drafting its policy on the proactive publication of clinical trial data, one concern expressed by the R&D industry was that the documents released might be of benefit to competitor companies, particularly if they contained commercially confidential information.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.